Fujitsu develops AI-based personalised cancer treatment

Aichi Cancer Center and Fujitsu have announced the development of an artificial intelligent (AI) solution able to select effective medical treatment from a wide range of drugs based on patients’ individual cancer types and various genomic variants. The effectiveness of the new solution has been verified in clinical trials by physicians at Aichi Cancer

Center. With current cancer genomic medicine in Japan, treatment plans are considered based on the patients’ unique circumstances, including the type of cancer and the actionable genomic variants detected in cancer cells. Combining the knowhow of Aichi Cancer Center in drug selection and Fujitsu’s AI-based data-integration technology, the new solution is able to sort and combine these data under common keywords and a single data format and generate a structured data of knowledge, called Knowledge Graph, in order to find the medications that are likely to be highly effective for each patient.